LOGIN  |  REGISTER
Assertio
Terns Pharmaceuticals

MultiPlan Announces Executive Leadership Changes

October 03, 2024 | Last Trade: US$6.45 1.24 23.80
  • Curren Katz Named Senior Vice President, Chief Data Science Officer
  • Tara O’Neil Promoted to General Counsel; Scott Mays Promoted to SVP, Legal and Deputy General Counsel

NEW YORK / Oct 03, 2024 / Business Wire / MultiPlan Corporation (“MultiPlan” or the “Company”) (NYSE: MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today announced an addition to its leadership team and two internal promotions within its Legal team, showcasing the company’s deep pool of talent.

Curren Katz, PhD has been appointed Chief Data Science Officer. In this newly created role, Katz will lead and unify the company’s efforts and accelerate its expertise in data science and AI. She joins MultiPlan from Johnson & Johnson’s (J&J) pharmaceuticals, where she served most recently as Global Head, Strategic Business Transformation after leading Data Science and Digital Health. Prior to J&J, Katz spent five years at Highmark Health, founding and leading the enterprise Data Science department covering payor and provider markets, with responsibility for strategic partnerships, AI Governance, and other key growth drivers. Her U.S. healthcare leadership experience also includes three years at Mount Sinai Beth Israel Medical Center.

Tara O’ Neil has been promoted to General Counsel from her former role as the Senior Vice President, Deputy General Counsel. O’Neil has spent more than thirty years at MultiPlan and played a pivotal role in the growth of MultiPlan and in developing the Legal Department. In her new role, O’Neil will serve as a key member of the executive team, responsible for MultiPlan’s multi-disciplinary legal organization including legal, regulatory compliance, corporate governance, client and provider contracting, and supporting the company’s talent acquisition and management needs.

Scott Mays has been promoted to Senior Vice President, Legal and Deputy General Counsel from his former role as Vice President, Legal and Associate General Counsel. Since joining MultiPlan in 2017, Mays has been a key member of the Legal Department and played a crucial role in developing the client contracting group and supporting corporate transactions. Prior to MultiPlan, Mays served as the Associate General Counsel at Tufts Health Plan.

“I am excited to welcome Curren to our team. She is a trusted thought leader who will create a refreshed blend of experience and perspective that position us well for continuing our evolution and transformation to help bend the healthcare cost curve for all,” said Travis Dalton, President and Chief Executive Officer of MultiPlan. “I am also equally thrilled for Tara and Scott. The internal promotions are an incredible testament to the dedication, innovation and excellence of our team and a reminder of the great talent we have within MultiPlan.”

About MultiPlan

MultiPlan is committed to bending the cost curve in healthcare by delivering transparency, fairness, and affordability to the US healthcare system. Our focus is on identifying medical savings, helping to lower out-of-pocket costs, and reducing or eliminating balance billing for healthcare consumers. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based, data and decision science, and analytics-based services. MultiPlan delivers value to more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit multiplan.com.

Astria Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB